More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/beta-Mannosylceramide [1334332-65-8]
Chemical Structure
Chemical Structure
Chemical Structure

beta-Mannosylceramide [1334332-65-8]

Research Use Only
AG-CR1-3621
AdipoGen Life Sciences
CAS Number1334332-65-8
DownloadMSDS
Product group Chemicals
Estimated Purity>95%
Molecular Weight858.3
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    beta-Mannosylceramide [1334332-65-8]
  • Delivery Days Customer
    10
  • CAS Number
    1334332-65-8
  • Certification
    Research Use Only
  • Estimated Purity
    >95%
  • Molecular Formula
    C50H99NO9
  • Molecular Weight
    858.3
  • Scientific Description
    Chemical. CAS: 1334332-65-8. Formula: C50H99NO9. MW: 858.3. Potent stimulator of invariant natural killer T (iNKT) cells. Induces strong antitumor immunity through a nitric oxide (NO) and TNF-alpha dependent mechansim, different compared to the IFN-gamma dependent mechanism of alpha-GalCer (AG-CN2-0014). Does not induce anergy of iNKT cells. - Potent stimulator of invariant natural killer T (iNKT) cells. Induces strong antitumor immunity through a nitric oxide (NO) and TNF-alpha dependent mechansim, different compared to the IFN-gamma dependent mechanism of alpha-GalCer (AG-CN2-0014). Does not induce anergy of iNKT cells.
  • SMILES
    CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](COC1OC(CO)C(O)C(O)C1O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • Mouse and human iNKT cell agonist beta-mannosylceramide reveals a distinct mechanism of tumor immunity: J.J. O'Konek, et al.; J. Clin. Invest. 121, 683 (2011)
  • NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma: S.R. Mattarollo, et al.; Blood 120, 3019 (2012)
  • beta-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy: J.J. O'Konek, et al.; Clin. Cancer Res. 19, 4404 (2013)